Resources
Joint Statements/Positions
Joint stakeholder statement on the implementation of the EHDS (2024)
Joint Statements/Positions
Joint Position Paper on Patient information on medicinal products – how to make it patient-centric? (2024)
Study
IPSOS perception study on non-prescription medicines and digital product information (2024)
Joint Statements/Positions
Multi-stakeholder statement on "Draft text of the European Health Data Space (EHDS) in trilogues sparks deep concerns in the European healthcare ecosystem" (2024)
Study
IQVIA Consumer Health x AESGP White Paper "Dynamics of Self-Care Medical Devices in Europe" (2024)
Joint Statements/Positions
Joint statement supporting the expansion of the use of Electronic Instructions For Use (eIFU) in the medical devices sector (2024)
Statement
AESGP Statement on the European Commission’s legislative proposal amending the IVDR and MDR (2024)
Joint Statements/Positions
Joint open letter: In anticipation of EUDAMED availability for mandatory use (2023)
Joint Statements/Positions
Stakeholder coalition calls for legislative refinement of the EHDS (2023)
Study
Brochure - Self-Care In Europe: Economic And Social Impact on Individuals and Society (2023)
Position Paper
AESGP Position Paper on the European Commission’s proposal for a revision of EU general pharmaceutical legislation (2023)
Guidance
Medical Devices - Manufacturer’s Declaration in relation to Regulation (EU) 2023/607
Position Paper
AESGP Position Paper on E-Commerce in self-care: challenges and opportunities (2023)
Study
Self-Care in Europe: Economic and Social Impact on Individuals and Society (AESGP, 2023)
Position Paper
AESGP Reply to the Feedback Procedure on the Commission's Proposal for a Regulation on Packaging and Packaging Waste (2023)
Joint Statements/Positions
Joint Statement on the Packaging and Packaging Waste Regulation's Single Market Legal Basis (2023)
Joint Statements/Positions
White Paper “Balancing challenges on Environment with access to medicines in Europe”: Impact assessment of policy options for Pharmaceuticals in the Environment and the use of Extended Producer Responsibility applied to human medicines (2023)
Joint Statements/Positions
Extended Environmental Risk Assessment (eERA) proposal: Proactively managing the environmental risks associated with the patient use of human medicinal products (2023)
Position Paper
AESGP Position Paper on the revision on Urban Waste Water Treatment Directive (2023)
Statement
AESGP Statement on European Commission’s legislative proposal amending the MDR (2023)
Joint Statements/Positions
Joint Statement on the Urban Waste Water Treatment Directive Proposal (2022)
Statement
AESGP Statement on the European Commission’s Communication “Save gas for a safe winter” (2022)
Position Paper
AESGP Reply to European Commission’s Regulation Proposal on the European Health Data Space (2022)
Joint Statements/Positions
Inter-Association Policy Statement on Responsible Manufacturing Effluent Management (2022)
Statement
AESGP Statement on the MDCG Guidance on borderline between medical devices and medicinal products under Regulation (EU) 2017/745 on medical devices (MDCG 2022 – 5) (2022)
Study
AESGP Summary Report “Self-Care in Europe: Economic and Social Impact on Individuals and Society” (2021)
Position Paper
AESGP pledge to GSCF’s Charter for Environmentally Sustainable Self-Care (2021)
Position Paper
AESGP Reply to European Commission's Regulation Proposal on Artificial Intelligence (2021)
Position Paper
AESGP Evidence Summary: Self-care in times of pandemic and beyond: looking back a year after (2021)
Position Paper
AESGP Position Paper on Paving the way for the digitalisation of the self-care sector (2021)
Joint Statements/Positions
European Stakeholder Group Statement - Maintaining the exchange of critical health data
Position Paper
AESGP Reply to European Commission’s Inception Impact Assessment on a European Health Emergency Preparedness and Response Authority - HERA (2021)
Position Paper
AESGP Position Paper on a reinforced EMA mandate - European Health Union (2021)
Joint Statements/Positions
AESGP, EFPIA and Medicines for Europe reflections on EMA – HMA – EC Key principles for electronic product information
Joint Statements/Positions
European Pharmaceutical Industry Statement on the Update on the Progress and Implementation of the EU Strategic Approach to Pharmaceuticals in the Environment
Statement
AESGP Reaction to European Commission’s Communication on the EU Pharmaceutical Strategy (2020)
Joint Statements/Positions
Joint EU-UK pharmaceutical industry response to Specialised Committee outcome
Joint Statements/Positions
EU Health Coalition: 10 recommendations to build a stronger EU Health Union
Joint Statements/Positions
EU Pharma Industry's joint statement on the European Parliament’s Resolution on Pharmaceuticals in the Environment
Position Paper
AESGP Reply to European Commission’s Roadmap for the Pharmaceutical Strategy (2020)
Position Paper
AESGP Position Paper on Shortages of medicinal products for citizens in Europe (2020)
Joint Statements/Positions
Joint Letter on the Need for a Mutual Recognition Agreement between the EU and UK
Statement
AESGP Reaction to European Commission’s Roadmap on the Pharmaceutical Strategy (2020)
Joint Statements/Positions
European Industry trade and supply chain needs to respond to COVID-19
Joint Statements/Positions
EU Health Coalition calls for more solidarity and coordinated EU action to tackle COVID-19
Joint Statements/Positions